23 results on '"Kuip, Evelien J. M."'
Search Results
2. Continuity of care for patients with de novo metastatic cancer during the COVID‐19 pandemic: A population‐based observational study.
- Author
-
Slotman, Ellis, Weijzen, Feike, Fransen, Heidi P., van Hoeve, Jolanda C., Huijben, Auke M. T., Kuip, Evelien J. M., Jager, Agnes, Kunst, Peter W. A., van Laarhoven, Hanneke W. M., Tol, Jolien, Tjan‐Heijnen, Vivianne C. G., Raijmakers, Natasja J. H., van der Linden, Yvette M., and Siesling, Sabine
- Subjects
COVID-19 pandemic ,CONTINUUM of care ,METASTASIS ,COVID-19 treatment ,CANCER treatment - Abstract
During the COVID‐19 pandemic recommendations were made to adapt cancer care. This population‐based study aimed to investigate possible differences between the treatment of patients with metastatic cancer before and during the pandemic by comparing the initial treatments in five COVID‐19 periods (weeks 1–12 2020: pre‐COVID‐19, weeks 12–20 2020: 1st peak, weeks 21–41 2020: recovery, weeks 42–53 2020: 2nd peak, weeks 1–20 2021: prolonged 2nd peak) with reference data from 2017 to 2019. The proportion of patients receiving different treatment modalities (chemotherapy, hormonal therapy, immunotherapy or targeted therapy, radiotherapy primary tumor, resection primary tumor, resection metastases) within 6 weeks of diagnosis and the time between diagnosis and first treatment were compared by period. In total, 74,208 patients were included. Overall, patients were more likely to receive treatments in the COVID‐19 periods than in previous years. This mainly holds for hormone therapy, immunotherapy or targeted therapy and resection of metastases. Lower odds were observed for resection of the primary tumor during the recovery period (OR 0.87; 95% CI 0.77–0.99) and for radiotherapy on the primary tumor during the prolonged 2nd peak (OR 0.84; 95% CI 0.72–0.98). The time from diagnosis to the start of first treatment was shorter, mainly during the 1st peak (average 5 days, p <.001). These findings show that during the first 1.5 years of the COVID‐19 pandemic, there were only minor changes in the initial treatment of metastatic cancer. Remarkably, time from diagnosis to first treatment was shorter. Overall, the results suggest continuity of care for patients with metastatic cancer during the pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study
- Author
-
van Oosterhout, Sanne P. C., Ermers, Daisy J. M., Ploos van Amstel, Floor K., van Herpen, Carla M. L., Schoon, Yvonne, Perry, Marieke, van Geel, Maartje, Kuip, Evelien J. M., and Engels, Yvonne
- Published
- 2021
- Full Text
- View/download PDF
4. Trajectories of health‐related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study
- Author
-
Versluis, Moyke A. J., primary, Raijmakers, Natasja J. H., additional, Baars, Arnold, additional, van den Beuken‐van Everdingen, Marieke H. J., additional, de Graeff, Alexander, additional, Hendriks, Mathijs P., additional, de Jong, Wouter K., additional, Kloover, Jeroen S., additional, Kuip, Evelien J. M., additional, Mandigers, Caroline M. P. W., additional, Sommeijer, Dirkje W., additional, van der Linden, Yvette M., additional, and van de Poll‐Franse, Lonneke V., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Trajectories of health‐related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study.
- Author
-
Versluis, Moyke A. J., Raijmakers, Natasja J. H., Baars, Arnold, van den Beuken‐van Everdingen, Marieke H. J., de Graeff, Alexander, Hendriks, Mathijs P., de Jong, Wouter K., Kloover, Jeroen S., Kuip, Evelien J. M., Mandigers, Caroline M. P. W., Sommeijer, Dirkje W., van der Linden, Yvette M., and van de Poll‐Franse, Lonneke V.
- Subjects
SYMPTOM burden ,CANCER patients ,QUALITY of life ,APPETITE loss ,CONTINUUM of care - Abstract
Background: Support for health‐related quality of life (HRQOL) is an essential part of cancer care in the final stages of life, yet empirical guidance regarding HRQOL and symptom trajectories is lacking. Aim: To assess the change in HRQOL and symptom burden in the last year of life in patients with advanced cancer and its association with health care–related factors, cancer‐specific treatment, and comorbidity. Methods: A prospective, multicenter, observational study in patients with advanced cancer (eQuiPe). Three monthly questionnaires included European Organization for Research and Treatment of Cancer Quality of Life‐C30 and reported continuity of care. Multivariable mixed‐effects analysis was used to assess the association between HRQOL and health care–related factors. Results: A total of 762 deceased patients were included with a mean age of 66 (SD, 10) years and 52% were male. The most common primary tumors were lung (29%), colorectal (20%), and breast cancer (13%). Mean overall HRQOL decreased in the last 9 months of life, with the greatest decrease in the last 3 months (β –16.2). Fatigue, pain, appetite loss, dyspnea, constipation, and nausea worsened significantly in the last year of life. Multimorbidity (β –7.5) and a better reported continuity of care (β 0.7) were both significantly associated with the trajectory of HRQOL. Conclusion: Mean overall HRQOL begins to decline 9 months before death, highlighting the need for early identification and (re)assessment of different symptoms as aspects of HRQOL follow different trajectories. Multimorbidity and reported continuity of care may be associated with the trajectory of HRQOL. Longitudinal results from the eQuiPe study show that the mean health‐related quality of life begins to decline 9 months before death in patients with advanced cancer. Higher perceived continuity with care is associated with an attenuated decline in health‐related quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
- Author
-
Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.
- Subjects
METASTATIC breast cancer ,LOBULAR carcinoma ,EPIDERMAL growth factor receptors ,METASTASIS ,HISTOPATHOLOGY ,POSITRON emission tomography - Abstract
Background: In metastatic breast cancer (MBC), [
18 F]fluorodeoxyglucose positron emission tomography/computed tomography ([18 F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18 F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18 F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18 F]FDG uptake was expressed as maximum standardized uptake value (SUVmax ) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18 F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18 F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18 F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18 F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18 F]FDG uptake, [18 F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
- Author
-
van Geel, Jasper J L, Boers, Jorianne, Elias, Sjoerd G, Glaudemans, Andor W J M, de Vries, Erik F J, Hospers, Geke A P, van Kruchten, Michel, Kuip, Evelien J M, Jager, Agnes, Menke-van der Houven van Oordt, Willemien C, van der Vegt, Bert, de Vries, Elisabeth G E, Schröder, Carolina P, Translational Immunology Groningen (TRIGR), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Medical Oncology, Internal medicine, and CCA - Imaging and biomarkers
- Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,Cancer Research ,SDG 3 - Good Health and Well-being ,Oncology - Abstract
PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis. METHODS In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to qualitative whole-body [18F]FES-PET evaluation and quantitative [18F]FES uptake in the corresponding metastasis. A review and meta-analysis regarding [18F]FES-PET diagnostic performance were performed. RESULTS Whole-body [18F]FES-PET assessment predicted ER expression in the biopsied metastasis with good accuracy: a sensitivity of 95% (95% CI, 89 to 97), a specificity of 80% (66 to 89), a positive predictive value (PPV) of 93% (87 to 96), and a negative predictive value (NPV) of 85% (72 to 92) in 181 of 200 evaluable patients. Quantitative [18F]FES uptake predicted ER immunohistochemistry in the corresponding metastasis with a sensitivity/specificity of 91%/69% and a PPV/NPV of 90%/71% in 156 of 200 evaluable patients. For bone metastases, PPV/NPV was 92%/81%. Meta-analysis with addition of our data has increased diagnostic performance and narrowed the 95% CIs compared with previous studies with a sensitivity/specificity of both 86% (81 to 90 and 73 to 93, respectively). CONCLUSION In this largest prospective series so far, we established the clinical validity of [18F]FES-PET to determine tumor ER status in MBC. In view of the high diagnostic accuracy of qualitatively assessed whole-body [18F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332 ).
- Published
- 2022
8. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients
- Author
-
Kuip, Evelien J. M., Zandvliet, Maarten L., Koolen, Stijn L. W., Mathijssen, Ron H. J., and van der Rijt, Carin C. D.
- Published
- 2017
- Full Text
- View/download PDF
9. Additional file 1 of Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study
- Author
-
van Oosterhout, Sanne P. C., Ermers, Daisy J. M., Ploos van Amstel, Floor K., van Herpen, Carla M. L., Schoon, Yvonne, Perry, Marieke, van Geel, Maartje, Kuip, Evelien J. M., and Engels, Yvonne
- Subjects
Data_FILES ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,ComputingMilieux_COMPUTERSANDSOCIETY - Abstract
Additional file 1. Topic list family caregivers. Microsoft Word document (DOC). In this additional file the topic list for the interviews with the family caregivers is reported.
- Published
- 2021
- Full Text
- View/download PDF
10. Additional file 2 of Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study
- Author
-
van Oosterhout, Sanne P. C., Ermers, Daisy J. M., Ploos van Amstel, Floor K., van Herpen, Carla M. L., Schoon, Yvonne, Perry, Marieke, van Geel, Maartje, Kuip, Evelien J. M., and Engels, Yvonne
- Subjects
ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,ComputingMilieux_COMPUTERSANDSOCIETY - Abstract
Additional file 2. Codebook interviews family caregivers. Microsoft Word document (DOC). In this additional file the final coding scheme for the interviews with the family caregivers is reported.
- Published
- 2021
- Full Text
- View/download PDF
11. Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer.
- Author
-
Kroon, Lente L., van Roij, Janneke, Korfage, Ida J., Reyners, An K. L., van den Beuken-van Everdingen, Marieke H. J., den Boer, Marien O., Creemers, Geert-Jan, de Graeff, Alexander, Hendiks, Mathijs P., Hunting, Jarmo C. B., de Jong, Wouter K., Kuip, Evelien J. M., van Laarhoven, Hanneke W. M., van Leeuwen, Lobke, van Lindert, Anne S. R., Mandigers, Caroline M. P.W., Nieboer, Peter, van der Padt-Pruijsten, Annemieke, Smilde, Tineke J., and Sommeijer, Dirkje W.
- Subjects
TUMOR treatment ,SENSORY perception ,ADVANCE directives (Medical care) ,QUALITY of life ,QUESTIONNAIRES - Abstract
Purpose: Advance Care Planning (ACP) is positively associated with the quality of care, but its impact on emotional functioning is ambiguous. This study investigated the association between perceptions of ACP involvement and emotional functioning in patients with advanced cancer.Methods: This study analyzed baseline data of 1,001 patients of the eQuiPe study, a prospective, longitudinal, multicenter, observational study on quality of care and quality of life in patients with advanced cancer in the Netherlands. Patients with metastatic solid cancer were asked to participate between November 2017 and January 2020. Patients' perceptions of ACP involvement were measured by three self-administered statements. Emotional functioning was measured by the EORTC-QLQ-C30. A linear multivariable regression analysis was performed while taking gender, age, migrant background, education, marital status, and symptom burden into account.Results: The majority of patients (87%) reported that they were as much involved as they wanted to be in decisions about their future medical treatment and care. Most patients felt that their relatives (81%) and physicians (75%) were familiar with their preferences for future medical treatment and care. A positive association was found between patients' perceptions of ACP involvement and their emotional functioning (b=0.162, p<0.001, 95%CI[0.095;0.229]) while controlling for relevant confounders.Conclusions: Perceptions of involvement in ACP are positively associated with emotional functioning in patients with advanced cancer. Future studies are needed to further investigate the effect of ACP on emotional functioning.Trial Registration Number: NTR6584 Date of registration: 30 June 2017 IMPLICATIONS FOR CANCER SURVIVORS: Patients' emotional functioning might improve from routine discussions regarding goals of future care. Therefore, integration of ACP into palliative might be promising. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients
- Author
-
Kuip, Evelien J. M., Zandvliet, Maarten L., Koolen, Stijn L. W., Mathijssen, Ron H. J., and van der Rijt, Carin C. D.
- Subjects
Male ,Dose-Response Relationship, Drug ,Reviews ,Confounding Factors, Epidemiologic ,Cancer Pain ,Analgesics, Opioid ,Fentanyl ,Sex Factors ,Pharmacogenetics ,Research Design ,Neoplasms ,Humans ,Female ,Aged - Abstract
Fentanyl is a strong opioid that is available for various administration routes, and which is widely used to treat cancer-related pain. Many factors influence the fentanyl pharmacokinetics leading to a wide inter- and intrapatient variability. This systematic review summarizes multiple studied factors that potentially influence fentanyl pharmacokinetics with a focus on implications for cancer patients. The use of CYP3A4 inhibitors and inducers, impaired liver function, and heating of the patch potentially influence fentanyl pharmacokinetics in a clinically relevant way. In elderly patients, current data suggest that we should carefully dose fentanyl due to alterations in absorption and metabolism. The influence of BMI and gender on fentanyl pharmacokinetics is questionable, most probably due to a large heterogeneity in the published studies. Pharmacogenetics, e.g. the CYP3A5*3 gene polymorphism, may influence fentanyl pharmacokinetics as well, although further study is warranted. Several other factors have been studied but did not show significant and clinically relevant effects on fentanyl pharmacokinetics. Unfortunately, most of the published papers that studied factors influencing fentanyl pharmacokinetics describe healthy volunteers instead of cancer patients. Results from the studies in volunteers may not be simply extrapolated to cancer patients because of multiple confounding factors. To handle fentanyl treatment in a population of cancer patients, it is essential that physicians recognize factors that influence fentanyl pharmacokinetics, thereby preventing potential side-effects and increasing its efficacy.
- Published
- 2016
13. Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer
- Author
-
Kuip, Evelien J. M., primary, Oldenmenger, Wendy H., additional, Thijs—Visser, Martine F., additional, de Bruijn, Peter, additional, Oosten, Astrid W., additional, Oomen—de Hoop, Esther, additional, Koolen, Stijn L. W., additional, Van der Rijt, Carin C. D., additional, and Mathijssen, Ron H. J., additional
- Published
- 2018
- Full Text
- View/download PDF
14. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients
- Author
-
Kuip, Evelien J. M., primary, Zandvliet, Maarten L., additional, Koolen, Stijn L. W., additional, Mathijssen, Ron H. J., additional, and van der Rijt, Carin C. D., additional
- Published
- 2016
- Full Text
- View/download PDF
15. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients
- Author
-
Oosten, Astrid W., primary, Abrantes, João A., additional, Jönsson, Siv, additional, de Bruijn, Peter, additional, Kuip, Evelien J. M., additional, Falcão, Amílcar, additional, van der Rijt, Carin C. D., additional, and Mathijssen, Ron H. J., additional
- Published
- 2016
- Full Text
- View/download PDF
16. Samen beslissen.
- Author
-
Kuip, Evelien J. M.
- Published
- 2021
17. Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy.
- Author
-
Kuip, Evelien J. M., Oldenmenger, Wendy H., Oomen-de Hoop, Esther, Verduijn, Gerda M., Thijs-Visser, Martine F., de Bruijn, Peter, van Meerten, Esther, Koolen, Stijn L. W., Mathijssen, Ron H. J., and van der Rijt, Carin C. D.
- Subjects
- *
HEAD tumors , *NECK tumors , *CONFIDENCE intervals , *FENTANYL , *T-test (Statistics) , *PAIN management , *TREATMENT effectiveness , *XEROSTOMIA , *SUBLINGUAL drug administration , *MUCOSITIS , *CHEMORADIOTHERAPY , *TUMOR treatment - Abstract
Over 90% of patients treated for head and neck cancer with curatively aimed chemo or bioradiotherapy will develop painful mucositis and xerostomia. Sublingually delivered fentanyl (SDL) is a rapid acting opioid to treat breakthrough pain. It is unclear how SDL is absorbed by the mucosa of these patients. Therefore, the aim of this study was to investigate the effects of mucositis and xerostomia on the absorption of SDL. Thirteen patients who received chemo or bioradiotherapy (RT), were given a single dose of fentanyl: Before start of RT, 3 and 6 weeks after start of RT, and 6 weeks after finishing RT. Pharmacokinetic samples were taken. The primary endpoint was the relative difference (RD) between systemic exposure to fentanyl (area under the curve; AUC) at baseline (AUCbaseline) and fentanyl AUC in the presence of mucositis grade ≥2. The secondary endpoint was the RD between AUCbaseline and fentanyl AUC in the presence of xerostomia, which were analyzed by means of a paired t-test on log-transformed data. Mucositis resulted in a 12.7% higher AUC (n = 13; 95% CI: −10.7% to +42.2%, p = 0.29) compared to baseline levels and xerostomia resulted in a 22.4% lower AUC (n = 8; 95% CI: −51.9% to +25.3%, p = 0.25) compared to baseline levels. Mucositis grade ≥2 or xerostomia caused by chemo or bioradiotherapy does not significantly alter the systemic exposure to SDL. Patients with pain during and after chemo or bioradiotherapy may be safely treated with SDL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Decline in Smartphone-Assessed Physical Activity Level is Associated With Clinical Outcomes in Phase I/II Clinical Cancer Trials.
- Author
-
Brouwer CG, Douma JAJ, Kuip EJM, Zweegman S, van de Donk NWCJ, Hopman MTE, van Linde ME, Verheul HMW, and Buffart LM
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Treatment Outcome, Neoplasms therapy, Neoplasms mortality, Smartphone, Exercise
- Abstract
Background: A decline in physical function may be an early predictor for complications of cancer treatment. This study examined whether repeated objective smartphone measurements of physical activity and exercise capacity in patients with cancer are feasible during early-phase clinical trials (EPCTs) and whether a decline in physical function is associated with clinical outcomes., Methods: Physical activity (steps/day) and exercise capacity (6-minute walk test [6MWT]) were measured with a smartphone before EPCT start (T0) and after 4 weeks (T1) and 8 weeks (T2). Univariable logistic regression analyzed associations between a decline in step count (≥20%), 6MWT distance (≥10%), or deterioration of ECOG performance status (PS) and trial discontinuation at 8 weeks and 90 days. Cox proportional hazards models were used to examine associations with progression-free survival (PFS) and overall survival (OS), adjusting for trial phase (I vs II), cancer type (hematologic malignancy vs solid tumor), and PS (0 vs ≥1)., Results: Among 117 included patients, valid step count and 6MWT measurements were available for 96.6% and 76.7% of patients at T0, 74.4% and 53.3% at T1, and 89.7% and 54.4% at T2, respectively. Patients experiencing step count decline between T0 and T1 had higher odds of trial discontinuation at 8 weeks (odds ratio, 8.67; 95% CI, 1.94-61.43), and decline between T1 and T2 was associated with discontinuation at 90 days (odds ratio, 5.20; 95% CI, 1.43-21.14). Step count decline was significantly associated with shorter PFS (hazard ratio, 3.54; 95% CI, 2.06-6.08) and OS (hazard ratio, 2.31; 95% CI, 1.26-4.23). Declines in 6MWT distance or deterioration in ECOG PS were not associated with trial discontinuation or survival., Conclusions: Repeated smartphone measurements of physical activity are feasible in patients participating in EPCTs. Additionally, physical activity decline is significantly associated with trial discontinuation, PFS, and OS. Hence, we envision that objective smartphone measurements of physical activity will contribute to optimal treatment development for patients with cancer.
- Published
- 2024
- Full Text
- View/download PDF
19. Are specialist-provided end-of-life scenarios key to initiation of advance care planning in primary care? A mixed-methods study.
- Author
-
Poelman SW, Ermers DJM, Schers HJ, Vissers KCP, Veldhoven CMM, Kuip EJM, and Perry M
- Abstract
Objectives: Specialist-provided end-of-life scenarios (SP-EOLS) may improve advance care planning (ACP) implementation in primary care by helping overcome barriers such as uncertain prognosis and poor interprofessional collaboration. We aimed to explore the current use and potential impact of SP-EOLS on ACP in Dutch primary care., Methods: We performed a mixed-methods study. From patients discussed in a hospital-based academic palliative care multidisciplinary team meeting between 2016 and 2019 and died, we collected primary care electronic medical records data on SP-EOLS, actual EOLS, and ACP initiation and applied descriptive and comparative analyses. Subsequently, we interviewed general practitioners (GPs) and thematically analyzed the transcripts., Results: In 69.7% of 66 reviewed patient files, SP-EOLS were found. In patients whose GP had received SP-EOLS, ACP conversations were more often reported (92.0 vs. 61.0%, p = 0.006). From 11 GP interviews, we identified 4 themes: (1) SP-EOLS guide GPs, patients, and relatives when dealing with an uncertain future perspective; (2) SP-EOLS provide continuity of care between primary and secondary/tertiary care; (3) SP-EOLS should be tailored to the individual patient; and (4) SP-EOLS need to be personalized and uniformly transferred to GPs., Significance of Results: SP-EOLS may facilitate ACP conversations by GPs. They have the potential to help overcome existing barriers to ACP implementation by providing guidance and supporting interprofessional collaboration. Future research should focus on improving SP-EOLS and tailor them to the needs of all end users, focusing on improving their effect on ACP conversations.
- Published
- 2024
- Full Text
- View/download PDF
20. Clinical Validity of 16α-[ 18 F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
- Author
-
van Geel JJL, Boers J, Elias SG, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, Kuip EJM, Jager A, Menke-van der Houven van Oordt WC, van der Vegt B, de Vries EGE, and Schröder CP
- Subjects
- Humans, Female, Receptors, Estrogen metabolism, Positron Emission Tomography Computed Tomography methods, Positron-Emission Tomography methods, Multicenter Studies as Topic, Estradiol, Breast Neoplasms pathology
- Abstract
Purpose: Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[
18 F]fluoro-17β-estradiol positron emission tomography ([18 F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18 F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18 F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis., Methods: In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to qualitative whole-body [18 F]FES-PET evaluation and quantitative [18 F]FES uptake in the corresponding metastasis. A review and meta-analysis regarding [18 F]FES-PET diagnostic performance were performed., Results: Whole-body [18 F]FES-PET assessment predicted ER expression in the biopsied metastasis with good accuracy: a sensitivity of 95% (95% CI, 89 to 97), a specificity of 80% (66 to 89), a positive predictive value (PPV) of 93% (87 to 96), and a negative predictive value (NPV) of 85% (72 to 92) in 181 of 200 evaluable patients. Quantitative [18 F]FES uptake predicted ER immunohistochemistry in the corresponding metastasis with a sensitivity/specificity of 91%/69% and a PPV/NPV of 90%/71% in 156 of 200 evaluable patients. For bone metastases, PPV/NPV was 92%/81%. Meta-analysis with addition of our data has increased diagnostic performance and narrowed the 95% CIs compared with previous studies with a sensitivity/specificity of both 86% (81 to 90 and 73 to 93, respectively)., Conclusion: In this largest prospective series so far, we established the clinical validity of [18 F]FES-PET to determine tumor ER status in MBC. In view of the high diagnostic accuracy of qualitatively assessed whole-body [18 F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332).- Published
- 2022
- Full Text
- View/download PDF
21. Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.
- Author
-
Kuip EJM, Oldenmenger WH, Visser-Thijs MF, de Bruijn P, Oomen-de Hoop E, Mathijssen RHJ, Van der Rijt CCD, and Koolen SW
- Abstract
Background and Objectives: The cutaneous fentanyl patch is widely used to treat continuous pain in patients with cancer. Its use is hampered by a high inter- and intrapatient pharmacokinetic variability. Factors that influence this pharmacokinetic variability are largely unclear. The aim of these studies was to test if common patient variables, i) the use of the moderate CYP3A4 inhibitor aprepitant and ii) the localization of the fentanyl patch (upper arm versus thorax) influence systemic exposure to fentanyl in patients with cancer using a transdermal fentanyl patch., Results: The AUC
0-6 h of fentanyl was 7.1% (95% CI: -28% to +19%) lower if patients concurrently used aprepitant, compared to the period when patients used fentanyl only. The AUC0-4 h of fentanyl was 7.4% (95% CI: -22% to +49%) higher when the cutaneous fentanyl patch was applied to the upper arm compared to application at the thorax., Conclusions: Neither the concurrent use of aprepitant, nor the localization of the fentanyl patch showed a statistically significant influence on fentanyl pharmacokinetics., Methods: We performed two prospective cross-over pharmacokinetic intervention studies. Both studies had two eight-day study periods. At day 8 of each study period blood samples were collected for pharmacokinetic analysis. In each study 14 evaluable patients were included., Competing Interests: CONFLICTS OF INTEREST Evelien J.M. Kuip, Wendy H. Oldenmenger, Martine F. Thijs - Visser, Peter de Bruijn, Esther Oomen – de Hoop, Stijn L.W. Koolen and Ron H.J. Mathijssen have declared to have no conflicts of interest relevant to the content of this paper. Carin D.D. Van der Rijt received a grant from Kyowa Kirin International for a pharmacokinetic study on sublingual fentanyl.- Published
- 2018
- Full Text
- View/download PDF
22. Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer.
- Author
-
Westdorp H, Kuip EJM, van Oort IM, Kramers C, Gerritsen WR, and Vissers KCP
- Subjects
- Aged, Benzamides, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Drug Interactions, Humans, Male, Middle Aged, Nitriles, Pain drug therapy, Pain Management methods, Palliative Care methods, Phenylthiohydantoin therapeutic use, Prostatic Neoplasms, Castration-Resistant pathology, Analgesics, Opioid therapeutic use, Antineoplastic Agents therapeutic use, Fentanyl therapeutic use, Oxycodone therapeutic use, Phenylthiohydantoin analogs & derivatives, Prostatic Neoplasms, Castration-Resistant drug therapy
- Published
- 2018
- Full Text
- View/download PDF
23. Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma.
- Author
-
de Bruijn P, Kuip EJM, Lam MH, Mathijssen RHJ, and Koolen SLW
- Subjects
- Acetonitriles chemistry, Analgesics, Opioid pharmacology, Analgesics, Opioid therapeutic use, Calibration, Cancer Pain drug therapy, Chromatography, High Pressure Liquid instrumentation, Dose-Response Relationship, Drug, Fentanyl pharmacology, Humans, Morphine Derivatives pharmacology, Reference Standards, Reproducibility of Results, Solid Phase Extraction, Tandem Mass Spectrometry instrumentation, Analgesics, Opioid analysis, Chromatography, High Pressure Liquid methods, Fentanyl analysis, Morphine Derivatives blood, Tandem Mass Spectrometry methods
- Abstract
The aim of this study was to develop an assay for the quantification of hydromorphone, morphine, fentanyl and the metabolites norfentanyl, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma to support pharmacokinetic studies investigating the large interpatient variability in response to opioid treatment. For the quantitation of hydromorphone, morphine, fentanyl and its metabolite norfentanyl aliquots of 200μL human potassium EDTA plasma were deproteinized with deuterated internal standards in a mixture of acetonitrile and acetone, followed by a liquid-liquid extraction with 4% ammonium hydroxide and ethyl acetate. Morphine-3ß-glucuronide and morphine-6ß-glucuronide were extracted by a solid phase extraction using 10mM ammonium carbonate pH 8.8 and a deuterated internal standards solution. Morphine, hydromorphone, fentanyl and norfentanyl were separated on an Aquity UPLC
® BEH C18 column 1.7μm, 100mm×2.1mm at 50°C. Separation, was achieved on a gradient of methanol with an overall run time of 6min. The compounds were quantified by triple-quadrupole mass spectrometry in the positive ion electrospray ionization mode. Morphine-3ß-glucuronide and morphine-6ß-glucuronide were separated on a VisionHT C18-P; 3μm 2.1×50mm, column at 40°C on a gradient of acetonitrile, with an overall run time of 10min. Both methods were precise and accurate, with within-run and between-run precisions within acceptable limits and accuracy ranging from 84.0 to 105.5%. The methods were successfully applied to support clinical pharmacological studies in patients treated with opioids for the treatment of moderate to severe cancer-related pain., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.